Advertisment

The Rising Costs and Effectiveness of New Obesity Drugs

author-image
Dr. Jessica Nelson
New Update
NULL

The Rising Costs and Effectiveness of New Obesity Drugs

Advertisment

As the epidemic of obesity continues to grow globally, the medical world has responded with the development of new and effective drugs aimed at managing weight. While these drugs have shown promising results, their high costs and the need for long-term usage have sparked debate and concern. One pharmaceutical company is striving to offer a solution that could potentially eliminate the need for continuous medication.

Advertisment

Cost-Effectiveness of Weight Management Drugs

Recent research has focused on assessing the cost-effectiveness of weight management drugs in Canada. One study found that semaglutide 2.4 mg was the most cost-effective treatment when compared to orlistat and the current standard of care at a willingness to pay threshold of CAD 50,000 per quality-adjusted life year (QALY). However, the economic burden of obesity in Canada was estimated to be US 40.3 billion in 2019, a figure predicted to increase fourfold to US 162.35 billion by 2060. This underlines the urgent need for cost-effective treatment options for obesity, a condition associated with numerous health complications that can be reduced with successful weight loss.

High Costs of GLP-1 Drugs

Advertisment

The introduction of glucagon-like peptide 1 receptor agonist drugs (GLP-1 drugs) has stirred a debate about the high costs of healthcare in the U.S. These drugs, like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, are effective in promoting weight loss in patients with type 2 diabetes and obesity. However, their steep price tags, exceeding $1,000 for a month’s supply, have led to patients considering medical tourism to countries like Canada, the U.K., and France for more affordable treatment options. Efforts to reduce obesity drug costs include utilizing rebates, copay cards, patient assistant programs, and compound pharmacies.

Weight Loss Injectables: Efficacy vs. Cost

Weight loss injectables such as Zepbound and other GLP-1 drugs have gained attention due to their effectiveness in aiding weight loss. They work by mimicking the GLP-1 hormone, reducing appetite and increasing feelings of satiety, leading to significant weight loss in patients. Despite their effectiveness, these drugs come with a high cost and potential long-term use. The side effects, including nausea, diarrhea, vomiting, or constipation, coupled with the cost of these drugs, limited insurance coverage, and the potential for weight regain, are major hindrances to wider use.

Advertisment

New Developments in Obesity Drugs

New drugs like Wegovy, Zepbound, Ozempic, and Mounjaro, approved to treat obesity and type 2 diabetes, are part of a new class of medications called GLP-1s. These drugs make weight loss more effortless by mimicking the hormone glucagon like peptide 1, released in the gut when we eat. They have been effective in aiding significant weight loss, with semaglutide showing an average weight loss close to 15% and tirzepatide reaching bariatric surgery levels of weight loss with a near 21% weight loss. While these drugs are relatively safe, with common side effects being nausea, constipation, and acid reflux, their high costs remain a significant barrier.

Despite these challenges, there are over 50 drugs currently in clinical trials and ongoing research and development efforts in the field of anti-obesity drugs. The goal is to create affordable and effective treatments that can help curb the obesity epidemic and reduce the economic burden it imposes. The journey towards a 'one and done' solution continues, as researchers and pharmaceutical companies alike strive to strike the right balance between cost and efficacy.

Advertisment
Chat with Dr. Medriva !